AZD0292
/ AstraZeneca
- LARVOL DELTA
Home
Next
Prev
1 to 7
Of
7
Go to page
1
February 27, 2025
A Study to Assess the Safety, Tolerability, and Pharmacokinetics of a Single Ascending Dose of AZD0292 In Healthy Participants
(clinicaltrials.gov)
- P1 | N=32 | Completed | Sponsor: AstraZeneca | Active, not recruiting ➔ Completed
Trial completion
October 30, 2024
A Study to Assess the Safety, Tolerability, and Pharmacokinetics of a Single Ascending Dose of AZD0292 In Healthy Participants
(clinicaltrials.gov)
- P1 | N=32 | Active, not recruiting | Sponsor: AstraZeneca | Trial completion date: Nov 2024 ➔ Feb 2025 | Trial primary completion date: Nov 2024 ➔ Feb 2025
Trial completion date • Trial primary completion date
September 25, 2024
A Study to Assess the Safety, Tolerability, and Pharmacokinetics of a Single Ascending Dose of AZD0292 In Healthy Participants
(clinicaltrials.gov)
- P1 | N=32 | Active, not recruiting | Sponsor: AstraZeneca | Recruiting ➔ Active, not recruiting | N=17 ➔ 32
Enrollment change • Enrollment closed
August 21, 2024
A Study to Assess the Safety, Tolerability, and Pharmacokinetics of a Single Ascending Dose of AZD0292 In Healthy Participants
(clinicaltrials.gov)
- P1 | N=17 | Recruiting | Sponsor: AstraZeneca | N=32 ➔ 17
Enrollment change
May 29, 2024
A Study to Assess the Safety, Tolerability, and Pharmacokinetics of a Single Ascending Dose of AZD0292 In Healthy Participants
(clinicaltrials.gov)
- P1 | N=32 | Recruiting | Sponsor: AstraZeneca | N=24 ➔ 32
Enrollment change
April 18, 2024
A Study to Assess the Safety, Tolerability, and Pharmacokinetics of a Single Ascending Dose of AZD0292 In Healthy Participants
(clinicaltrials.gov)
- P1 | N=24 | Recruiting | Sponsor: AstraZeneca | Not yet recruiting ➔ Recruiting
Enrollment open
March 15, 2024
A Study to Assess the Safety, Tolerability, and Pharmacokinetics of a Single Ascending Dose of AZD0292 In Healthy Participants
(clinicaltrials.gov)
- P1 | N=24 | Not yet recruiting | Sponsor: AstraZeneca
New P1 trial
1 to 7
Of
7
Go to page
1